New: our own Hairmetry line. Every ingredient explained

Encyclopedia · immunomodulator

Cyclosporine (ciclosporin)

A transplant and psoriasis immunosuppressant that makes hair grow as a side effect and works off-label in alopecia areata, but is toxic to kidneys and blood pressure.

Prescription medicine, used off-label for hair Cost $$ Safety: serious

hair loss

What it is

Cyclosporine is an oral immunosuppressant. Excess hair growth (hypertrichosis) is a common effect of cyclosporin, minoxidil and diazoxide (Tosi 1994). It is used off-label for alopecia areata alongside steroids, methotrexate and azathioprine; a European expert consensus lists these as the off-label systemic options (Rudnicka 2024). Prescription-only. It is not a pattern-baldness treatment.

How it works

For alopecia areata, the effect is immunosuppression. Separately, in cultured human scalp follicles cyclosporine lowered the Wnt-pathway brake SFRP1 in the dermal papilla, which pointed researchers to WAY-316606 (Hawkshaw 2018).

What the studies show

  • A meta-analysis of mostly non-randomised studies (344 people) found a responder proportion of 73% (66% alone, 78% with systemic steroids). Recurrence was 55% on cyclosporine alone versus 28% with steroids (Husein-ElAhmed 2022).
  • A Cochrane review of 63 trials found the evidence for oral prednisolone or cyclosporine versus placebo "very uncertain"; only baricitinib had high-certainty benefit (Mateos-Haro 2023).
  • No evidence shows that topical cyclosporine grows hair.

How it's used in studies

Side effects and safety

  • Kidney toxicity, high blood pressure and infection risk are the main systemic risks. Excess hair on the face and body is common. It is not suitable in pregnancy without specialist advice. Relapse after stopping is common.

Bottom line

Cyclosporine is a specialist-only option for alopecia areata when JAK inhibitors are unavailable, supported by weak studies. It has no role in pattern hair loss. Discuss with a doctor.

Fun facts

  • Its hairy side effect pointed researchers to a new hair-growth target (SFRP1) rather than to the drug itself (Hawkshaw 2018).

Studies 5

Husein-ElAhmed H, Steinhoff M. Efficacy and predictive factors of cyclosporine A in alopecia areata. J Dermatolog Treat. 2022

Design
meta analysis
People
344
Who
people with alopecia areata (mostly non-randomised studies)

Tested: oral cyclosporine, alone or with steroids

Result: Responder proportion 73% (66% alone, 78% with steroids); recurrence 55% alone vs 28% with steroids.

Read the study ↗

Mateos-Haro M et al. Treatments for alopecia areata: a network meta-analysis. Cochrane Database Syst Rev. 2023

Design
systematic review
People
4,817
Who
people with alopecia areata (63 RCTs)

Tested: all studied treatments

Result: Baricitinib was the only treatment with high-certainty evidence of benefit; for oral prednisolone or cyclosporine versus placebo the evidence was very uncertain.

Read the study ↗

Hawkshaw NJ et al. Identifying novel strategies for treating human hair loss disorders: cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles. PLoS Biol. 2018

Design
in vitro
Who
human scalp follicles in organ culture

Tested: cyclosporine A and WAY-316606

Result: Cyclosporine lowered SFRP1 and WAY-316606 reproduced the effect, boosting hair shaft production and delaying regression.

Read the study ↗

Rudnicka L et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024

Design
guideline
Who
European hair specialists

Tested: systemic treatments for alopecia areata

Result: Lists off-label glucocorticoids, methotrexate, cyclosporine and azathioprine alongside approved JAK inhibitors.

Read the study ↗

Tosi A et al. Drug-induced hair loss and hair growth. Drug Saf. 1994

Design
review
Who
reports of drug-related hair changes

Tested: various drugs

Result: Hypertrichosis is a common effect of cyclosporin, minoxidil and diazoxide.

Read the study ↗